Drug Trial Radar · NCT03129555
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Apr 1, 2023
Primary completion
Mar 31, 2027
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- Herlev and Gentofte HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in venous thromboembolism across Danish hospitals.
Conditions
- Deep Vein Thrombosis
- Pulmonary Embolism
Interventions
Dabigatran Etexilate Oral CapsuleDrug
After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Rivaroxaban Oral TabletDrug
After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Edoxaban Oral TabletDrug
After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Apixaban Oral TabletDrug
After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary efficacy outcome: a composite endpoint of new venous thromboembolism or all-cause death.Time frame: 6 months.
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Aarhus University Hospital
Aarhus, Denmark
Bispebjerg and Frederiksberg Hospital
Copenhagen, Denmark
Bispebjerg Hospital
Copenhagen NV, Denmark
Rigshospitalet
Copenhagen Ø, Denmark
Amager Hospital
Copenhagen S, Denmark
Esbjerg Hospital
Esbjerg, Denmark
Nordsjællands Hospital - Frederiksund
Frederikssund, Denmark
Herlev Gentofte Hospital
Gentofte Municipality, Denmark
Glostrup Hospital - Department of Emergency Medicine
Glostrup Municipality, Denmark
Glostrup Hospital - Department of Medicine / Cardiology
Glostrup Municipality, Denmark
Glostrup Hospital - Department of Neurology
Glostrup Municipality, Denmark
Herlev-Gentofte Hospital - Department of Medicine
Herlev, Denmark
Nordsjællands Hospital - Hillerød
Hillerød, Denmark
Hjørring Hospital
Hjørring, Denmark
Holbæk Hospital
Holbæk, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Næstved Hospital
Næstved, Denmark
Odense University Hospital - Department of Cardiology
Odense, Denmark
Odense University Hospital - Department of Emergency Medicine
Odense, Denmark
Odense University Hospital - Department of Geriatrics
Odense, Denmark
Bornhoms Hospital
Rønne, Denmark
Zealand University Hospital - Department of Neurology
Roskilde, Denmark
Zealand University Hospital Roskilde - Department of Cardiology
Roskilde, Denmark
Slagelse Hospital
Slagelse, Denmark
Odense University Hospital Svendborg
Svendborg, Denmark
Vejle Hospital
Vejle, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.